尿液肾小管生物标志物对肾脏结局的预测价值:EMPA-KIDNEY研究观察
在EMPA-KIDNEY试验5100例CKD患者中,评估9种尿肾小管生物标志物能否在KFRE基础上改善肾衰竭预测。中位随访3.5年,1191例进展、461例治疗性肾衰竭;KFRE对治疗性肾衰竭区分度优秀(C-index 0.858),加MCP-1、KIM-1和EGF后预测肾病进展绝对改善0.038。
要点
- KFRE对CKD患者治疗性肾衰竭区分度优秀,对肾病进展中等。
- 在KFRE基础上加MCP-1、KIM-1和EGF可小幅改善风险预测。
- 从3种扩展到全部9种生物标志物预测改善有限。
核心结论
- 在多种病因CKD患者中,将MCP-1、KIM-1和EGF三种尿肾小管生物标志物加入KFRE可改善CKD进展风险估计。
研究设计与样本
- EMPA-KIDNEY随机试验中5100例有进展风险的CKD患者,测量9种尿肌酐校正肾小管生物标志物,中位随访3.5年。
主要发现
- 随访期间1191例发生肾病进展,461例发生治疗性肾衰竭。
- KFRE对治疗性肾衰竭C-index为0.858(0.840-0.874),对肾病进展为0.724(0.705-0.743)。
- 加入MCP-1、KIM-1和EGF后,预测肾衰竭绝对差异0.014(0.009-0.024),预测肾病进展绝对差异0.038(0.026-0.053)。
- 从3种扩展到全部9种生物标志物,预测改善仅轻微。
临床怎么用
- 对CKD患者可考虑在KFRE基础上检测尿MCP-1、KIM-1和EGF以细化进展风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The kidney failure risk equation showed excellent discrimination for treated kidney failure outcome in patients with CKD. In a wide range of causes of CKD, urine tubular biomarkers improved prediction of kidney disease progression beyond established clinical risk models. EGF, kidney injury molecule-1, and monocyte chemoattractant protein-1 added the most prognostic value. BACKGROUND: Urine tubular biomarkers have previously been associated with chronic kidney disease (CKD) progression independently of eGFR and albuminuria. We evaluated whether nine urine tubular biomarkers could improve prediction of kidney failure beyond serum creatinine and urine albumin‑creatinine ratio among adults with CKD. METHODS: Among 5100 participants in Study of Heart and Kidney Protection With Empagliflozin, a randomized trial that assessed the effects of empagliflozin 10 mg versus matching placebo among patients with CKD at risk of progression, nine urine creatinine-indexed tubular biomarkers were measured, including α -1 microglobulin, dickkopf-3, EGF, interleukin-18, kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), neutrophil gelatinase-associated lipocalin, uromodulin, and human cartilage glycoprotein-40. Outcomes were kidney disease progression (treated kidney failure, renal death, or sustained ≥40% eGFR decline) and treated kidney failure (maintenance dialysis or kidney transplant). Relative to models based on the linear predictor of the kidney failure risk equation (KFRE), improvements in discrimination were estimated with further addition of the nine tubular biomarkers using absolute difference in Uno C-index. RESULTS: Over a median 3.5 years of follow-up, 1191 participants experienced kidney disease progression and 461 experienced treated kidney failure. KFRE demonstrated excellent discrimination for treated kidney failure (C-index 0.858 [0.840-0.874]) and moderate discrimination for kidney disease progression (0.724 [0.705-0.743]). Addition of three biomarkers (MCP-1, KIM-1, and EGF) most strongly associated with CKD outcomes yielded some further improvement in predicting kidney failure (absolute difference 0.014 [0.009-0.024]) and kidney disease progression (0.038 [0.026-0.053]). Prediction of kidney outcomes was only slightly improved when further expanding from three to all nine tubular biomarkers. CONCLUSION: In a wide range of causes of CKD, adding three urine tubular biomarkers (MCP-1, KIM-1, and EGF) to KFRE improves estimates of risk of CKD progression. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: NCT03594110 .
引用
- Malijan GB, Herrington WG, Judge PK, et al. Predictive Value of Urine Tubular Biomarkers on Kidney Outcomes: Observations from EMPA-KIDNEY. Clin J Am Soc Nephrol. 2026. PMID: 42690923. doi:10.2215/CJN.0000001203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。